🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 100 of 173

  1. US 8895717

    Delivery of siRNA by neutral lipid compositions

    Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8889638

    Stimulus-triggered prodrugs

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8889672

    Compounds, formulations, and methods of protein kinase C inhibition

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8889658

    Phosphonate compounds

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8889635

    Dendrimer conjugates

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8889623

    Immunostimulatory nanoparticles and related compositions, methods and systems

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8889156

    Calcium-binding agents induce hair growth and/or nail growth

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8889140

    Compositions and methods for tissue repair

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8889121

    Bacterium comprising a regulated rfaH nucleic acid

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8889743

    Inhibition of filovirus entry into cells and uses thereof

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8883771

    Bivalent inhibitors of IAP proteins and therapeutic methods using the same

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8883502

    Expandable cell source of neuronal stem cell populations and methods for obtaining and using them

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8883507

    Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8883144

    Treatment of pulmonary vascular remodeling with neprilysin

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8883174

    Compositions for stimulation of mammalian innate immune resistance to pathogens

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8883948

    Methods for extensive dark curing based on visible-light initiated, controlled radical polymerization

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8883841

    Oncogenic ras-specific cytotoxic compound and methods of use thereof

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8883729

    Nanolipoprotein particles and related compositions, methods and systems

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8883214

    Implantable delivery vehicle for ocular delivery of muscarinic antagonists

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8883189

    Intraocular encapsulation of oxygenic bacteria

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8883155

    Methods for treating hematopoietic malignancies

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8883154

    Antibody-mediated modulation of allergy

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8877253

    Cellular extracts

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8877796

    Spiro-oxindole MDM2 antagonists

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8877797

    Methods for treating Parkinson's disease using pro-neurogenic compounds

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8877721

    Small activating RNA molecules and methods of use

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8877215

    Compounds with modifying activity enhanced under hypoxic conditions

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8877208

    Multivalent nanoemulsion vaccines

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8877188

    Detection and treatment of non-dermal fibrosis

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8877161

    GM1-like peptides and uses thereof

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8877195

    Monoclonal antibodies to fibrin

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8871199

    Compositions and methods to promote implantation and engrafment of stem cells

    Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8871794

    Small-molecule agonists for type-2 orexin receptor

    Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8871447

    Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence

    Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8865873

    Internalizing human monoclonal antibodies targeting prostate cancer cells in situ

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8865750

    Small molecule inhibitors of RGS proteins

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8865867

    Lectins and uses thereof

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8865719

    Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8865199

    Biomatrix composition and methods of biomatrix seeding

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8865469

    Methods of transforming a Listeria

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8865914

    Fluorescent probes for detection of copper

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8865187

    Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8859736

    Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof

    Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8859520

    Methods for therapy of neurodegenerative disease of the brain

    Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8858925

    Pegylated fibrinogen precursor molecule

    Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8859727

    Bioactive FUS1 peptides and nanoparticle-polypeptide complexes

    Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8859716

    Degradable thiol-ene polymers

    Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8859499

    Method of enhancing efficacy of blood transfusions

    Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.